Department of Advanced Therapeutics, BC Cancer Agency, 675 West 10th Ave., Vancouver, British Columbia, Canada V5Z1L3.
J Pharm Sci. 2010 May;99(5):2295-308. doi: 10.1002/jps.21988.
Triggered release of liposomal contents following tumor accumulation and mild local heating is pursued as a means of improving the therapeutic index of chemotherapeutic drugs. Lysolipid-containing thermosensitive liposomes (LTSLs) are composed of dipalmitoylphosphatidylcholine (DPPC), the lysolipid monostearoylphosphatidylcholine (MSPC), and poly(ethylene glycol)-conjugated distearoylphosphatidylethanolamine (DSPE-PEG(2000)). We investigated the roles of DSPE-PEG(2000) and lysolipid in the functional performance of the LTSL-doxorubicin formulation. Varying PEG-lipid concentration (0-5 mol%) or bilayer orientation did not affect the release; however, lysolipid (0-10 mol%) had a concentration-dependent effect on drug release at 42 degrees C in vitro. Pharmacokinetics of various LTSL formulations were compared in mice with body temperature controlled at 37 degrees C. As expected, incorporation of the PEG-lipid increased doxorubicin plasma half-life; however, PEG-lipid orientation (bilayer vs. external leaflet) did not significantly improve circulation lifetime or drug retention in LTSL. Approximately 70% of lysolipid was lost within 1 h postinjection of LTSL, which could be due to interactions with the large membrane pool of the biological milieu. Considering that the present LTSL-doxorubicin formulation exhibits significant therapeutic activity when used in conjunction with mild heating, our current study provided critical insights into how the physicochemical properties of LTSL can be tailored to achieve better therapeutic activity.
在肿瘤积累和轻度局部加热的情况下,触发脂质体内容物的释放被认为是提高化疗药物治疗指数的一种手段。含有溶血磷脂的热敏脂质体 (LTSL) 由二棕榈酰磷脂酰胆碱 (DPPC)、溶血磷脂单硬脂酰磷脂酰胆碱 (MSPC) 和聚乙二醇化二硬脂酰磷脂酰乙醇胺 (DSPE-PEG(2000)) 组成。我们研究了 DSPE-PEG(2000) 和溶血磷脂在 LTSL-阿霉素制剂功能性能中的作用。改变 PEG-脂质浓度 (0-5 mol%) 或双层取向不会影响释放;然而,溶血磷脂 (0-10 mol%) 在 42°C 体外对药物释放具有浓度依赖性。在体温控制在 37°C 的小鼠中比较了各种 LTSL 制剂的药代动力学。正如预期的那样,PEG-脂质的掺入增加了阿霉素的血浆半衰期;然而,PEG-脂质取向 (双层与外层) 并没有显著改善 LTSL 的循环寿命或药物保留。LTSL 注射后 1 小时内约有 70%的溶血磷脂丢失,这可能是由于与生物环境中的大量膜池相互作用所致。考虑到目前的 LTSL-阿霉素制剂在与温和加热结合使用时表现出显著的治疗活性,我们目前的研究为如何调整 LTSL 的物理化学性质以获得更好的治疗活性提供了重要的见解。